Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have the "wet" (neovascular) form of age-related macular degeneration (a condition where abnormal blood vessels grow under the retina)
• People who have been receiving injections into the eye (called anti-VEGF therapy) to treat this condition for more than one year
• People whose treating doctor switched their treatment to a specific medication called aflibercept 8 mg before July 31, 2025
• People who were receiving those eye injections at intervals of less than 12 weeks before the switch to aflibercept 8 mg

Who may not be able to join:

• People with severe short-sightedness, defined by specific eye measurements (confirm with trial site)
• People with a condition called angioid streaks, which involves crack-like lines in a layer at the back of the eye
• People with moderate or severe damage to the blood vessels in the eye caused by diabetes (diabetic retinopathy)
• People with a history of fluid build-up in the central part of the retina related to diabetes (diabetic macular edema)
• People with a history of uveitis, which is inflammation inside the eye
• People with a history of a blocked vein in the retina (retinal vein occlusion)
• People with a history of a specific inherited eye condition affecting the central retina called pseudovitelliform macular dystrophy
• People who are under a formal legal guardianship or curatorship arrangement
• Women who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.